<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056222</url>
  </required_header>
  <id_info>
    <org_study_id>CF2 Rev.1 IMP</org_study_id>
    <nct_id>NCT03056222</nct_id>
  </id_info>
  <brief_title>CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>CF²</acronym>
  <official_title>CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Med-Pro GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Med-Pro GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the acute procedure and safety outcomes as well as long
      term clinical outcomes of 2 groups of patients treated with the HeartLight® Endoscopically
      Guided Laser Ablation (EGLA) or a commercially available Contact Force Sensing Irrigated
      Radiofrequency (RF) Ablation Catheter plus, at the operator's discretion, 3D
      Electroanatomical Mapping (EAM) for the treatment of Paroxysmal Atrial Fibrillation (PAF).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from symptomatic, recurrent atrial fibrillation (AF) off of anti-arrhythmic drugs</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Recurrent AF is defined as any documented episode of AF lasting more than 30 seconds after a blanking period of 90 days post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute procedure success</measure>
    <time_frame>30 minutes post procedure</time_frame>
    <description>Confirmation of electrical isolation with a circular mapping catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure and fluoroscopy time</measure>
    <time_frame>During procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications</measure>
    <time_frame>From procedure to 12 months post procedure</time_frame>
    <description>E.g. major bleeding requiring intervention, phrenic nerve palsy, pericardial tamponade, thrombo-embolic events, pulmonary vein (PV) -stenosis, atrial-to-esophageal fistula, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from symptomatic, recurrent Atrial Tachy Arrhythmia (ATA) off of anti-arrhythmic drugs</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Recurrent ATA is defined as any documented episode of ATA lasting more than 30 seconds after a blanking period of 90 days post procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>HeartLight® EGLA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with the endoscopically guided laser ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contact Force Sensing Irrigated RF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation catheter</intervention_name>
    <description>Ablation of paroxysmal atrial fibrillation</description>
    <arm_group_label>HeartLight® EGLA</arm_group_label>
    <arm_group_label>Contact Force Sensing Irrigated RF ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must not have undergone a previous ablation for the treatment of PAF

          -  AF Type - Diagnosed with symptomatic paroxysmal atrial fibrillation (PAF) where PAF
             is defined as recurrent (two or more) episodes of AF that terminate spontaneously in
             less than seven days, usually less than 48 hours

        Exclusion Criteria:

          -  Atrial fibrillation secondary to a reversible cause or of non-cardiac origin

          -  Diagnosed with persistent atrial fibrillation defined as recurrent episodes lasting
             more than 7 and less than 365 days

          -  More than 4 electrical cardioversions in the year prior to enrollment but not
             including cardioversions performed within 48 hours of arrhythmia onset

          -  Documented left atrial thrombus on imaging

          -  Cannot be removed from anti-arrhythmic drugs for other reasons than atrial
             fibrillation

          -  New York Heart Association (NYHA) functional Class III or Class IV heart failure

          -  Left ventricular ejection fraction &lt; 30%

          -  Left atrial size &gt; 55 mm as measured in the parasternal antero-posterior view

          -  Myocardial infarction within 60 days prior to enrolment

          -  Woman of childbearing potential who is pregnant, lactating or not using adequate
             birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Metzner, PD Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doris Wächter, Dr</last_name>
    <phone>+49 171 3767676</phone>
    <email>waechter@imedpro.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Knut M Scharnberger, Dipl.Phys.</last_name>
    <phone>+49 171 3766666</phone>
    <email>scharnberger@imedpro.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Arnold, Dr. med.</last_name>
      <phone>0+49 9131 8535000</phone>
      <email>martin.arnold@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Metzner, PD Dr</last_name>
      <phone>+49 40 28902305</phone>
      <email>a.metzner@asklepios.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
